Methylphenidate patch for children with ADHD
About this title
Read the official source — NCT00466791This study evaluated the safety of Methylphenidate Transdermal System for people with ADHD.
Understand this study
What did researchers investigate?
This study evaluated the safety of Methylphenidate Transdermal System for people with ADHD.
Who was this study for?
Listed age limits: 6 years to 12 years.
- Listed locations
- IrvineSee all locations and recruitment
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
Study information
- Recruitment status
- Completed
- Enrollment listed in the registry
- 93
- Sponsor
- Noven Therapeutics
- Sponsor type
- Biotech company
- Study type
- Drug
- Intervention type
- Drug
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
- Locations
- United States
- Age range
- From 6 Years to 12 Years
- Official registry ID
- NCT00466791
- Official title
Show the full official title
A Phase II, Randomized, Double-blind, Multi-center, Placebo-controlled, Dose Optimization, Analog Classroom, Crossover Study Designed to Assess the Time Course of Treatment Effect, Tolerability and Safety of Methylphenidate Transdermal System (MTS) in Pediatric Patients Aged 6-12 With Attention-Deficit/Hyperactivity Disorder (ADHD)
Looking for a study you can join?
Explore recruiting studiesRecruitment & locations
Irvine
Interested in joining this study?
Questions about this study
What did researchers investigate?
This study evaluated the safety of Methylphenidate Transdermal System for people with ADHD.
Who is behind this study?
The study sponsor is Noven Therapeutics.
Did this study involve medication?
Yes. The study involved medication, including Methylphenidate Transdermal System.
Who was this study for?
Listed age limits: 6 years to 12 years.
